Search Results

Rafarma Pharmaceuticals (OTC: RAFA). The Company is pleased to announce that it has completed the restructuring, accounting and balance sheet procedures required to comply with GAAP auditing standards.

Rafarma Pharmaceuticals - We are pleased to announce that Rapharma and its CEO Raivo Unt have entered into a preliminary agreement with Kelun Lifesciences Ltd, a pharmaceutical company based in Sri Lanka, on 17 November 2023.

Representatives of Rafarma Pharmaceuticals, Inc. visited Uzbekistan and discussed the prospects for the company’s development in the territory of the innovative research and production pharmaceutical cluster “Tashkent Pharma Park”.

Rafarma Pharmaceuticals, Inc. OTC: is an international biotechnological and pharmaceutical company that combines research centers and modern pharmaceutical production that meets international GMP standards.

Rafarma Pharmaceuticals, Inc. is expanding its production capabilities as it is in active negotiations for the acquisition of two machines from BOBST, one of the world’s leading suppliers of substrate processing, printing and converting equipment and services for the label, flexible packaging, folding carton and corrugated board industries.

Rafarma Pharmaceuticals, Inc.OTC:(RAFA) The scientific and technical council of the Agency for the Development of the Pharmaceutical Industry of Uzbekistan recognized the Rafarma Pharmaceuticals’ project for the construction of the Tashkent plant as the largest innovative project of the industrial zone of the Tashkent Pharma Park pharmaceutical cluster.

Rafarma Pharmaceuticals, Inc.OTC: is pleased to announce that RAFA is in active meetings the City Scientific University of Istanbul to establish a nuclear medicine and proton therapy center at the university.

Rafarma Pharmaceuticals, Inc.OTC: is pleased to announce its newly formulated strategies for aggressive global growth in 2021/2022.

Rafarma Pharmaceuticals, Inc. OTC: is pleased to announce its joint venture with the entity known as The Pharmaceutical Industry Development Agency of Uzbekistan which is essentially the Health Department of Uzbekistan.

The November layoffs are the second known workforce reduction this year for Marinus Pharmaceuticals, which previously announced disappointing Phase III results for ganaxolone in two clinical trials.